First-line PD-1/PD-L1 inhibitor followed by carboplatin (carbo)-based chemotherapy (chemo) or the reverse sequence in cisplatin-ineligible metastatic urothelial cancer (mUC) patients (pts) Meeting Abstract

  

Authors:	Wei, X. X.; Lundgren, K.; Teo, M. Y.; Rosenberg, J. E.; Koshkin, V. S.; Grivas, P.; Carril, L.; Castellano, D. E.; Velho, P.; Hahn, N. M.; McKay, R. R.; Raggi, D.; Necchi, A.; Kanesvaran, R.; Alerasool, P.; Gaines, J.; Morrison, L.; Powles, T.; Bellmunt, J.; Sonpavde, G.
Abstract Title:	First-line PD-1/PD-L1 inhibitor followed by carboplatin (carbo)-based chemotherapy (chemo) or the reverse sequence in cisplatin-ineligible metastatic urothelial cancer (mUC) patients (pts)
Meeting Title:	54th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	36
Issue:	15 Suppl.
Meeting Dates:	2018 Jun 1-5
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2018-05-20
Language:	English
ACCESSION:	WOS:000442916005381
DOI:	10.1200/JCO.2018.36.15_suppl.e16517
PROVIDER:	wos
Notes:	Meeting Abstract: e16517 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/169680